Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04252625 · ClinicalTrials.gov registry record · Phase 2
Trial of Quercetin, Bromelain, Rye Flower Pollen & Papain on Reducing Severity of Radiation-Induced Prostatitis
A Phase 2 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT04252625 is a Phase 2 study that was terminated before completion, run by University of Utah. The registered enrollment target is 10 participants.
The verdict
NCT04252625, a Phase 2 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study will assess the difference in prostatitis symptoms in men with localized prostate cancer following brachytherapy taking Q-Urol relative to placebo.
Interventions
- DRUG Placebo
- DRUG Q-Urol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-11-14 |
| Est. Completion | 2024-01-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04252625
The ClinicalTrials.gov registry entry for NCT04252625 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04252625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04252625 about?
NCT04252625 is a clinical study titled "Trial of Quercetin, Bromelain, Rye Flower Pollen & Papain on Reducing Severity of Radiation-Induced Prostatitis". This study will assess the difference in prostatitis symptoms in men with localized prostate cancer following brachytherapy taking Q-Urol relative to placebo.
What is the current status of trial NCT04252625?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2022-11-14. Estimated completion is 2024-01-25.
What interventions are being tested in trial NCT04252625?
The interventions under investigation include: Placebo (DRUG), Q-Urol (DRUG).
Who is sponsoring clinical trial NCT04252625?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.